ascites

Summary

Summary: Accumulation or retention of free fluid within the peritoneal cavity.

Top Publications

  1. ncbi Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research
    Emma Kipps
    The Institute of Cancer Research Royal Marsden Hospital, Medicine, Downs Road, Sutton SM2 5PT, UK
    Nat Rev Cancer 13:273-82. 2013
  2. ncbi Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis
    Marlene Pasquet
    EA3035, Institut Claudius Regaud, University Toulouse III, Faculte des sciences pharmaceutiques, Toulouse, F 31062, France
    Int J Cancer 126:2090-101. 2010
  3. pmc Antitumor activity of silver nanoparticles in Dalton's lymphoma ascites tumor model
    Muthu Irulappan Sriram
    Department of Biotechnology, Division of Molecular and Cellular Biology, Kalasalingam University, Tamilnadu, India
    Int J Nanomedicine 5:753-62. 2010
  4. pmc Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors
    Ardian Latifi
    Women s Cancer Research Centre, Royal Women s Hospital, Victoria, Australia
    PLoS ONE 7:e46858. 2012
  5. ncbi Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers
    Kathryn M Burleson
    Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA
    Gynecol Oncol 93:170-81. 2004
  6. ncbi PleurX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites: a NICE Medical Technology Guidance
    Judith White
    CEDAR, Cardiff and Vale University Health Board, Cardiff, Wales, UK
    Appl Health Econ Health Policy 10:299-308. 2012
  7. ncbi Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients
    Zheng Zhang
    Research Center for Biological Therapy, The Institute of Translational Hepatology, Beijing 302 Hospital, Beijing, China
    J Gastroenterol Hepatol 27:112-20. 2012
  8. ncbi Radiofrequency ablation for hepatocellular carcinoma abutting the diaphragm: the value of artificial ascites
    Hyunchul Rhim
    Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam Gu, Seoul, Korea
    Abdom Imaging 34:371-80. 2009
  9. pmc Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis
    Nadzeya Goncharenko-Khaider
    Departement De Microbiologie et Infectiologie, Faculte de Medecine, Universite de Sherbrooke, 3001, 12ième Avenue Nord, Sherbrooke, J1H 5N4, Canada
    Mol Cancer 11:84. 2012
  10. pmc Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis
    Richard B Bankert
    Department of Microbiology and Immunology, The State University of New York, University at Buffalo, Buffalo, New York, United States of America
    PLoS ONE 6:e24420. 2011

Detail Information

Publications347 found, 100 shown here

  1. ncbi Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research
    Emma Kipps
    The Institute of Cancer Research Royal Marsden Hospital, Medicine, Downs Road, Sutton SM2 5PT, UK
    Nat Rev Cancer 13:273-82. 2013
    Malignant ascites presents a considerable clinical challenge to the management of ovarian cancer, but also provides a wealth of opportunities for translational research...
  2. ncbi Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis
    Marlene Pasquet
    EA3035, Institut Claudius Regaud, University Toulouse III, Faculte des sciences pharmaceutiques, Toulouse, F 31062, France
    Int J Cancer 126:2090-101. 2010
    ..Cells closely associated with tumoral cells, named hospicells, have been recently isolated from the ascites of ovarian cancer patients...
  3. pmc Antitumor activity of silver nanoparticles in Dalton's lymphoma ascites tumor model
    Muthu Irulappan Sriram
    Department of Biotechnology, Division of Molecular and Cellular Biology, Kalasalingam University, Tamilnadu, India
    Int J Nanomedicine 5:753-62. 2010
    ..efficacy of biologically synthesized silver nanoparticles (AgNPs) as an antitumor agent using Dalton's lymphoma ascites (DLA) cell lines in vitro and in vivo...
  4. pmc Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors
    Ardian Latifi
    Women s Cancer Research Centre, Royal Women s Hospital, Victoria, Australia
    PLoS ONE 7:e46858. 2012
    Tumor cells in ascites are a major source of disease recurrence in ovarian cancer patients...
  5. ncbi Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers
    Kathryn M Burleson
    Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA
    Gynecol Oncol 93:170-81. 2004
    ..The current paradigm that ascites spheroids are non-adhesive leaves their contribution to ovarian carcinoma dissemination undefined...
  6. ncbi PleurX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites: a NICE Medical Technology Guidance
    Judith White
    CEDAR, Cardiff and Vale University Health Board, Cardiff, Wales, UK
    Appl Health Econ Health Policy 10:299-308. 2012
    The PleurX peritoneal drainage catheter for drainage of malignant ascites in a community setting has been evaluated by the NICE Medical Technologies Evaluation Programme...
  7. ncbi Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients
    Zheng Zhang
    Research Center for Biological Therapy, The Institute of Translational Hepatology, Beijing 302 Hospital, Beijing, China
    J Gastroenterol Hepatol 27:112-20. 2012
    ..There was a significant reduction in the volume of ascites in patients treated with UC-MSC transfusion compared with controls (P < 0.05)...
  8. ncbi Radiofrequency ablation for hepatocellular carcinoma abutting the diaphragm: the value of artificial ascites
    Hyunchul Rhim
    Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam Gu, Seoul, Korea
    Abdom Imaging 34:371-80. 2009
    ..RF ablation with assistance of the use of artificial ascites is a simple and safe technique for treating a hepatic dome tumor abutting the diaphragm...
  9. pmc Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis
    Nadzeya Goncharenko-Khaider
    Departement De Microbiologie et Infectiologie, Faculte de Medecine, Universite de Sherbrooke, 3001, 12ième Avenue Nord, Sherbrooke, J1H 5N4, Canada
    Mol Cancer 11:84. 2012
    b>Ascites may affect the progression of ovarian cancer (OC)...
  10. pmc Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis
    Richard B Bankert
    Department of Microbiology and Immunology, The State University of New York, University at Buffalo, Buffalo, New York, United States of America
    PLoS ONE 6:e24420. 2011
    ..growth is initially very slow and progressive within the peritoneal cavity with an ultimate development of tumor ascites, spontaneous metastasis to the lung, increasing serum and ascites levels of CA125, and the retention of tumor-..
  11. ncbi Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy
    Diane Seimetz
    Fresenius Biotech GmbH, Frankfurter Ring 193a, D 80807 München, Munich, Germany
    Cancer Treat Rev 36:458-67. 2010
    ..Catumaxomab has been approved in the European Union since April 2009 for the i.p. treatment of malignant ascites (MA) in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible...
  12. ncbi Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients
    Trevor G Shepherd
    Department of Pharmacology, Dalhousie University, 5850 College Street, Halifax, Nova Scotia, Canada B3H 1X5
    Nat Protoc 1:2643-9. 2006
    ..A simple protocol of obtaining primary epithelial ovarian cancer (EOC) cells from the ascites fluid removed from patients with high-grade ovarian cancer is also described...
  13. ncbi Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study
    Walter H Gotlieb
    McGill University, Jewish General Hospital, Montreal, QC, Canada
    Lancet Oncol 13:154-62. 2012
    Targeting of VEGF is a potential therapeutic option in patients with malignant ovarian ascites. We present the final results of a multicentre study of the efficacy and safety of aflibercept, a potent inhibitor of both VEGF and placental ..
  14. ncbi Evaluation of pharmacokinetics of 111In-labeled VNB-PEGylated liposomes after intraperitoneal and intravenous administration in a tumor/ascites mouse model
    Yi Yu Lin
    Biomedical Imaging and Radiological Sciences, National Yang Ming University, Taipei, Taiwan, Republic of China
    Cancer Biother Radiopharm 24:453-60. 2009
    ..p.) and intravenous (i.v.) administration in a C26/tk-luc colon carcinoma ascites mouse model. IVNBPL was prepared by labeling VNB-encapsulated PEGylated liposomes with 111In-oxine...
  15. ncbi Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites
    Thomas Sersté
    Institut National de la Santé et de la Recherche Médicale Unité 773, Centre de recherche Biomedicale Bichat Beaujon, Paris, France
    Hepatology 52:1017-22. 2010
    Beta-blockers may have a negative impact on survival in patients with cirrhosis and refractory ascites. The aim of this study was to evaluate the effect of the administration of beta-blockers on long-term survival in patients with ..
  16. ncbi Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM
    Steffen Runz
    Tumor Immunology Programme D010, German Cancer Research Center, Im Neuenheimer Feld 580, D 69120 Heidelberg, Germany
    Gynecol Oncol 107:563-71. 2007
    ..Given the emerging role of exosomes in tumor progression, we investigated whether cytoplasmic CD24 expression is correlated with the secretion of CD24 in exosomes...
  17. ncbi Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death
    Douglas M Heuman
    Department of Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA
    Hepatology 40:802-10. 2004
    ..MELD score, persistent ascites, and low serum sodium (<135 meq/L) were independent predictors of early mortality...
  18. ncbi Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model
    Annette T Byrne
    Center for Reproductive Sciences, University of California, San Francisco, San Francisco, California 94143, USA
    Clin Cancer Res 9:5721-8. 2003
    ..It is characterized by diffuse peritoneal carcinomatosis and often by large volumes of i.p. ascites. Because vascular endothelial growth factor (VEGF), also known as vascular permeability factor, increases ..
  19. ncbi Proinvasive properties of ovarian cancer ascites-derived membrane vesicles
    Laura E Graves
    Department of Cellular and Molecular Biology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Cancer Res 64:7045-9. 2004
    Malignant ovarian ascites are rich in cellular components, membrane-bound vesicles, and soluble proteins...
  20. ncbi Ovarian cancer metastasis: integrating insights from disparate model organisms
    Honami Naora
    Department of Molecular Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Nat Rev Cancer 5:355-66. 2005
    ..Genetic analysis of border-cell migration in the Drosophila melanogaster ovary provides clues that will improve our understanding of ovarian cancer metastasis at the molecular level, and also might lead to potential therapeutic targets...
  21. ncbi Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors
    Marek Nowak
    Department of Gynecologic Surgery, Polish Mother s Memorial Hospital Research Institute, Poland
    Neuro Endocrinol Lett 31:375-83. 2010
    ..factor-beta1 (TGF-beta1) and interferon-gamma (IFN-gamma) in serum and the tumor microenvironment (cyst fluid, ascites) in women with ovarian cancer or benign ovarian tumors to find the differences in their immunological status...
  22. pmc Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers
    Cynthia Kuk
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M5G 1L5, Canada
    Mol Cell Proteomics 8:661-9. 2009
    ..We performed an in-depth proteomics analysis of ovarian cancer ascites fluid...
  23. ncbi Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation
    Dorina Belotti
    Laboratory of Biology, Department of Oncology, Mario Negri Institute for Pharmacological Research, 24125 Bergamo, Italy
    Cancer Res 63:5224-9. 2003
    ..Levels of MMP9 (pro and activated form) and proMMP2 in ascites correlated with VEGF and with the ascitic volume in nude mice bearing human ovarian carcinoma xenografts (HOC22 ..
  24. pmc Screening and identification of biomarkers in ascites related to intrinsic chemoresistance of serous epithelial ovarian cancers
    He Huang
    Department of Gynecology Oncology, Sun Yat sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, PR China
    PLoS ONE 7:e51256. 2012
    ..The aim of this study was to screen and identify distinctive biomarkers in ascites of serous EOC associated with intrinsic chemoresistance.
  25. ncbi Ovarian ascites-derived Hospicells promote angiogenesis via activation of macrophages
    Magali Castells
    EA4553, Institut Claudius Regaud, F 31062 Toulouse, France
    Cancer Lett 326:59-68. 2012
    ....
  26. ncbi Natural history of patients hospitalized for management of cirrhotic ascites
    Ramon Planas
    Liver Section, Department of Gastroenterology, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    Clin Gastroenterol Hepatol 4:1385-94. 2006
    Since the International Ascites Club published the diagnostic criteria of refractory ascites (RA) and hepatorenal syndrome (HRS), there have been few studies assessing the natural history of ascites...
  27. ncbi Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis
    Francesco Salerno
    Policlinco IRCCS San Donato and Dipartimento di Scienze Medico Chirurgiche, Universita di Milano, Milano, Italy
    Liver Int 30:937-47. 2010
    b>Ascites is a frequent complication of cirrhosis and portal hypertension, because of the increase of the sinusoidal hydrostatic pressure. Cirrhosis accounts for over 75% of episodes of ascites...
  28. ncbi Niche-dependent tumorigenic capacity of malignant ovarian ascites-derived cancer cell subpopulations
    Ehood Katz
    Rappaport Faculty of Medicine and Research Institute, Technion Israel Institute of Technology, Haifa, Israel
    Clin Cancer Res 15:70-80. 2009
    ..cellular microenvironment in supporting the growth of human cancer cells freshly harvested from malignant ovarian ascites and to determine whether there are differences among subsets of ascites-derived cancer cells in terms of ..
  29. pmc Limitations of the MELD score in predicting mortality or need for removal from waiting list in patients awaiting liver transplantation
    Daniel Gotthardt
    Department of Internal Medicine IV, University Hospital of Heidelberg, Heidelberg, Germany
    BMC Gastroenterol 9:72. 2009
    ..The relative shortage of organ donors renders the allocation algorithms of organs essential. The optimal strategy based on scoring systems and/or waiting time is still under debate...
  30. ncbi Proteomic analysis of microvesicles derived from human colorectal cancer ascites
    Dong Sic Choi
    Department of Life Science and Division of Molecular and Life Sciences, Pohang University of Science and Technology, Pohang, Republic of Korea
    Proteomics 11:2745-51. 2011
    The presence of malignant ascites in the peritoneal cavity is a poor prognostic indicator of low survival rate...
  31. ncbi PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction
    Kaoru Abiko
    Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    Clin Cancer Res 19:1363-74. 2013
    ..Programmed cell death 1 ligand 1 (PD-L1) is known to suppress immune system and to be expressed in cancer cells. The purpose of this study is to elucidate the function of PD-L1 in peritoneal dissemination...
  32. ncbi Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3)
    Michael Jäger
    TRION Research GmbH, Martinsried, Germany
    Cancer Res 72:24-32. 2012
    Patients with malignant ascites secondary to primary carcinomas benefit from intraperitoneal therapy with the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3)...
  33. ncbi VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5
    Daniel Herr
    Department of Obstetrics and Gynecology, Ulm University Medical Centre, Ulm, Germany
    Gynecol Oncol 127:210-6. 2012
    To evaluate the role of VEGF-dependent Claudin 5 production for the development of ascites via influencing endothelial permeability in peritoneal tissue of ovarian cancer patients.
  34. pmc Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer
    Limin Hu
    Center for Reproductive Sciences, University of California at San Francisco 94143, USA
    Am J Pathol 161:1917-24. 2002
    Ovarian cancer is characterized by rapid growth of solid intraperitoneal tumors and production of large volumes of ascites. Our previous studies of intraperitoneal ovarian carcinoma in an athymic mouse model demonstrated that a ..
  35. ncbi A bivariate mixture model analysis of body weight and ascites traits in broilers
    S Zerehdaran
    Animal Breeding and Genetics Group, Wageningen Institute of Animal Science, The Netherlands
    Poult Sci 85:32-8. 2006
    ..of the present study was to use bivariate mixture models to study the relationships between body weight (BW) and ascites indicator traits...
  36. ncbi Hepatic venous pressure gradient in cirrhosis: correlation with the size of varices, bleeding, ascites, and child's status
    M Wadhawan
    Department of Gastroenterology, G B Pant Hospital, New Delhi, 110002, India
    Dig Dis Sci 51:2264-9. 2006
    ..The HVPG was comparable between hepatitis B- and hepatitis C virus-related cirrhotics (P = 0.8). Cirrhotics with ascites had a higher HVPG than those without ascites (18.5 +/- 5.6 vs 16.6 +/- 7.6 mm Hg; P = 0.02)...
  37. ncbi Disease-induced variability of genetic correlations: ascites in broilers as a case study
    K H de Greef
    Institute for Animal Science and Health, Lelystad, The Netherlands
    J Anim Sci 79:1723-33. 2001
    ..b>Ascites in broilers is such a disease...
  38. ncbi A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites
    Nicoletta Colombo
    Istituto Europeo di Oncologia, Divisione di Ginecologia, Via Ripamonti, Milano, Italy
    Gynecol Oncol 125:42-7. 2012
    ..Aflibercept inhibits ascites formation and reduces tumor burden in an ovarian cancer model...
  39. ncbi Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer
    Yoko Hasumi
    Division of Genetic Therapeutics, Jichi Medical School, Tochigi 329 0498, Japan
    Cancer Res 62:2019-23. 2002
    ..and stimulating endothelial growth, is thought to be responsible for fluid accumulation and angiogenesis in ascites tumors...
  40. ncbi CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers
    Ilona Kryczek
    Tulane University Health Science Center, New Orleans, LA 70112, USA
    Cancer Res 65:465-72. 2005
    ..To examine tumor angiogenesis in the tumor microenvironment, we studied malignant ascites and tumors of patients with untreated ovarian carcinoma...
  41. ncbi Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review
    Filippo Bellati
    Institute of Gynecology and Obstetrics, Sapienza University, Rome, Italy
    Invest New Drugs 28:887-94. 2010
    Malignant ascites resistant to conventional drugs frequently affects ovarian cancer patients at the end of life...
  42. pmc Guidelines on the management of ascites in cirrhosis
    K P Moore
    The UCL Institute of Hepatology, Royal Free and University College Medical School, UCL, Rowland Hill St, London NW3 2PF, UK
    Gut 55:vi1-12. 2006
  43. pmc Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer
    G Scambia
    Department of Gynecology and Obstetrics, Catholic University, Rome, Italy
    Br J Cancer 71:354-6. 1995
    ..0009). Multivariate analysis revealed that IL-6 positivity has an independent value...
  44. ncbi Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?
    Sebastian Kobold
    Department of Oncology Hematology Bone Marrow Transplantation with the Section Pneumology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Oncologist 14:1242-51. 2009
    Despite overall improvements in oncological care in the palliative setting, symptomatic malignant ascites remains a severe clinical problem. This form of effusion is known to be widely resistant to established modes of systemic therapy...
  45. ncbi Pharmacokinetics, micro-SPECT/CT imaging and therapeutic efficacy of (188)Re-DXR-liposome in C26 colon carcinoma ascites mice model
    Liang Cheng Chen
    Institute of Nuclear Energy Research, Taoyuan, Taiwan
    Nucl Med Biol 35:883-93. 2008
    ..pegylated liposomal doxorubicin ((188)Re-DXR-liposome) were investigated in the C26 murine colon carcinoma ascites mouse model...
  46. ncbi Ovarian cancer ascites protects from TRAIL-induced cell death through alphavbeta5 integrin-mediated focal adhesion kinase and Akt activation
    D Lane
    Departement De Microbiologie et Infectiologie, Faculte de Medecine, Universite de Sherbrooke, Sherbrooke, Canada
    Oncogene 29:3519-31. 2010
    ..We have earlier shown that ovarian cancer ascites induces Akt activation and protect tumor cells from TRAIL-induced apoptosis...
  47. ncbi Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model
    Limin Hu
    Center for Reproductive Sciences, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, San Francisco, California 94143 0556, USA
    Clin Cancer Res 11:6966-71. 2005
    Ovarian cancer is characterized by i.p. carcinomatosis and massive ascites. Vascular endothelial growth factor (VEGF) plays a pivotal role in tumor angiogenesis and vascular leakage leading to ascites...
  48. pmc The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
    Markus M Heiss
    Department of Surgery, Cologne Merheim Medical Center, University of Witten Herdecke, Cologne, Germany
    Int J Cancer 127:2209-21. 2010
    Malignant ascites is a common manifestation of advanced cancers, and treatment options are limited...
  49. ncbi Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer
    Shengming Dai
    Department of Oncology, Institute of Clinical Medicine, The Fourth Hospital Affiliated to Guangxi Medical University, Liuzhou, People s Republic of China
    Mol Ther 16:782-90. 2008
    ..In this study we report the phase I clinical trial of the ascites-derived exosomes (Aex) in combination with the granulocyte-macrophage colony-stimulating factor (GM-CSF) in the ..
  50. ncbi Ascitic fluid infection in patients with hepatitis B virus-related liver cirrhosis: culture-negative neutrocytic ascites versus spontaneous bacterial peritonitis
    Seung Up Kim
    Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
    J Gastroenterol Hepatol 25:122-8. 2010
    Ascitic fluid infection (AFI) consists of culture-negative neutrocytic ascites (CNNA) and spontaneous bacterial peritonitis (SBP)...
  51. ncbi Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity
    Rohann J M Correa
    Translational Ovarian Cancer Research Program, London Regional Cancer Program, London, Ontario, Canada
    Gynecol Oncol 125:441-50. 2012
    ..We propose that metastatic epithelial ovarian cancer (EOC) is a potential therapeutic target for the oncolytic agent, Myxoma virus (MYXV)...
  52. ncbi [Measurement of hepatic venous pressure gradient in liver cirrhosis: relationship with the status of cirrhosis, varices, and ascites in Korea]
    Moon Young Kim
    Department of Internal Medicine and Institute of Lifelong Health, Yonsei University Wonju College of Medicine, Wonju, Korea
    Korean J Hepatol 14:150-8. 2008
    ..The aim of this study was to determine the relationships between HVPG and the complications or status of cirrhosis...
  53. ncbi Effect of prebiotic on gut development and ascites incidence of broilers reared in a hypoxic environment
    F Solis de los Santos
    Poultry Production and Product Safety Research Unit, Agricultural Research Service, United States Department of Agriculture, Fayetteville, Arkansas 72701, USA
    Poult Sci 84:1092-100. 2005
    ..selected for an increased growth rate and improved feed conversion, but they are also more susceptible to ascites. Ascites occurs when there is an imbalance between available oxygen and the oxygen demand of the broiler...
  54. ncbi Dilutional hyponatremia in patients with cirrhosis and ascites
    Almudena Porcel
    Servicio de Aparato Digestivo, Hospital Universitario Puerta del Mar, c Ana de Viya 21, 11009, Cadiz, Spain
    Arch Intern Med 162:323-8. 2002
    ..To analyze the predisposing factors, modifications of vasoactive systems, and prognosis of patients with cirrhosis and hyponatremia...
  55. ncbi Complications of acute pancreatitis: clinical and CT evaluation
    Emil J Balthazar
    Radiology Department, New Bellevue Hospital, 3rd Floor, Room 3 W 37 3 W 42, 462 First Avenue, New York, NY 10016, USA
    Radiol Clin North Am 40:1211-27. 2002
    ..complications are mainly vascular or hemorrhagic in nature or involve the development of chronic pancreatic ascites. The early detection and objective evaluation of these complications by clinical and imaging methods leads to ..
  56. ncbi Ultrasound-guided biopsy of greater omentum: an effective method to trace the origin of unclear ascites
    Yanhong Que
    Department of Ultrasound, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
    Eur J Radiol 70:331-5. 2009
    Thickened greater omentum is encountered with high frequency in patients with ascites. The purpose of our study was to assess the utility of greater omentum biopsy under the guidance of ultrasound (US) in tracing the origin of unclear ..
  57. ncbi Changes in endogenous tissue glutathione level in relation to murine ascites tumor growth and the anticancer activity of cisplatin
    D Khynriam
    Cell and Tumor Biology Laboratory, Department of Zoology, School of Life Sciences, North Eastern Hill University, Shillong, India
    Braz J Med Biol Res 36:53-63. 2003
    ..Furthermore, lower doses of cisplatin in combination with buthionine sulfoximine (an inhibitor of glutathione synthesis) may be useful in cancer chemotherapy with decreased toxicity in the host...
  58. ncbi Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites
    Luke T Evans
    Advanced Liver Diseases Study Group, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 37:897-901. 2003
    The prevalence and natural history of spontaneous bacterial peritonitis in asymptomatic patients with ascites secondary to cirrhosis is unknown...
  59. ncbi Proteomics analysis of two mice hepatocarcinoma ascites syngeneic cell lines with high and low lymph node metastasis rates provide potential protein markers for tumor malignancy attributes to lymphatic metastasis
    Ming Zhong Sun
    Department of Biotechnology, Dalian Medical University, Dalian, P R China
    Proteomics 9:3285-302. 2009
    ..Current study narrows and provides certain specific protein candidates potentially playing important roles in LNM-associated cancers...
  60. ncbi BMP signalling controls the malignant potential of ascites-derived human epithelial ovarian cancer spheroids via AKT kinase activation
    Teresa M Peart
    Translational Ovarian Cancer Research Program, London Regional Cancer Program, 790 Commissioners Road East, Room A4 836, London, ON N6A 4L6, Canada
    Clin Exp Metastasis 29:293-313. 2012
    Epithelial ovarian cancer (EOC) cells have the ability to form multi-cellular aggregates in malignant ascites which dramatically alters cell signalling, survival, and metastatic potential...
  61. pmc Mesothelial cells stimulate the anchorage-independent growth of human ovarian tumour cells
    A P Wilson
    Oncology Research Laboratory, Derby City Hospital, UK
    Br J Cancer 59:876-82. 1989
    ..The relevance of the findings in the context of the pattern of spread of ovarian cancer is discussed...
  62. pmc Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites
    Marion G Ott
    Fresenius Biotech GmbH, Munich, Germany
    Int J Cancer 130:2195-203. 2012
    The trifunctional antibody catumaxomab is a targeted immunotherapy for the intraperitoneal treatment of malignant ascites. In a Phase II/III trial in cancer patients (n = 258) with malignant ascites, catumaxomab showed a clear clinical ..
  63. pmc Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites
    R Frances
    Department of Immunology, Hospital General Universitario, Pintor Baeza s n, Alicante, Spain
    Gut 53:860-4. 2004
    ....
  64. ncbi IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer
    Chi Wen Lo
    Department of Oncology, National Taiwan University Hospital, Institute of Toxicology, National Taiwan University College of Medicine, Nankang, Taiwan
    Cancer Res 71:424-34. 2011
    ..Here we report that sIL-6Rα is elevated in malignant ascites from ovarian cancer patients, where it is associated with poor prognosis...
  65. ncbi Pathogenesis of malignant ascites: Starling's law of capillary hemodynamics revisited
    J T Tamsma
    Department of General Internal Medicine, Leiden University Medical Center, The Netherlands
    Ann Oncol 12:1353-7. 2001
    ..As a result, so-called malignant ascites develops. Malignant ascites is a debilitating condition for which no effective anti-tumor therapy is available...
  66. ncbi Interferon-gamma in ascites could be a predictive biomarker of outcome in ovarian carcinoma
    Yu li Chen
    Graduate Institute of Anatomy and Cell Biology, College of Medicine, National Taiwan University, Taipei, Taiwan Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Cathay General Hospital, Taipei, Taiwan Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei, Taiwan
    Gynecol Oncol 131:63-8. 2013
    The ovarian cancer-associated ascites is an ideal material for evaluating the interaction between the host immune system and cancer cells in the tumor micro-environment...
  67. ncbi Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS
    Christophe Bureau
    Service d Hepato gastro enterologie, Fédération Digestive, CHU Toulouse Purpan, 31059 Toulouse Cedex, France
    J Hepatol 54:901-7. 2011
    Refractory ascites in patients with cirrhosis is associated with poor survival...
  68. ncbi Suppression of the invasive capacity of rat ascites hepatoma cells by knockdown of Slingshot or LIM kinase
    Yuji Horita
    Department of Biomolecular Sciences, Graduate School of Life Sciences, Tohoku University, Sendai, Miyagi, Japan
    J Biol Chem 283:6013-21. 2008
    ..In this assay, rat ascites hepatoma (MM1) cells were overlaid on a primary-cultured rat mesothelial cell monolayer and the number of cell ..
  69. ncbi Exosomes in the ascites of ovarian cancer patients: origin and effects on anti-tumor immunity
    Peng Peng
    Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing 100730, PR China
    Oncol Rep 25:749-62. 2011
    This study was performed to identify the origin of the ascites-derived exosomes from patients with ovarian cancer and to observe the effect of exosomes on anti-tumor immunity...
  70. pmc TGF-beta blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models
    Shan Liao
    Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Cancer Res 17:1415-24. 2011
    Ovarian cancer patients with malignant ascites have poor prognosis. The accumulation of ascites is caused by an imbalance between fluid extravasation from the blood vessels and reabsorption by lymphatic vessels...
  71. ncbi Peritoneal tuberculosis mimicking ovarian carcinoma with ascites and elevated serum CA-125: case report and review of literature
    B Piura
    Unit of Gynecologic Oncology, Soroka Medical Center and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
    Eur J Gynaecol Oncol 23:120-2. 2002
    ..The patient presented with ascites, abdominopelvic masses and elevated serum CA-125 (1,081 U/ml)...
  72. ncbi Survival following the development of ascites and/or peripheral oedema in primary biliary cirrhosis: a staged prognostic model
    Chun Wing Chan
    Liver Transplantation and Hepatobiliary Medicine, Royal Free Hospital, London, and Medical Statistics Unit, London School of Hygiene and Tropical Medicine, UK
    Scand J Gastroenterol 40:1081-9. 2005
    ..It is hypothesized that better precision could be achieved with a staged model, using ascites or peripheral oedema as a new starting-point for prediction.
  73. ncbi Catumaxomab: in malignant ascites
    James E Frampton
    Adis, Auckland, New Zealand
    Drugs 72:1399-410. 2012
    ..randomized, open-label, multicentre, pivotal phase II/III trial in patients with recurrent symptomatic malignant ascites due to EpCAM-positive tumours who were resistant to conventional chemotherapy...
  74. ncbi Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis
    A Gines
    Liver Unit, Hospital Clinic i Provincial, Barcelona, Spain
    Gastroenterology 111:1002-10. 1996
    Paracentesis associated with plasma expanders is widely used for the treatment of ascites in cirrhosis...
  75. pmc Primary effusion lymphoma: an untrivial differential diagnosis for ascites
    Funda Ceran
    Department of Internal Medicine, Social Security Education and Research Hospital, Ankara, Turkey
    Yonsei Med J 50:862-4. 2009
    ..The prognosis is usually poor despite treatment. Herein, the case of an immunocompetent patient with ascites and pleural effusion diagnosed as primary effusion lymphoma is presented and discuss the case in the light of the ..
  76. ncbi Predicting the advent of ascites and other complications in primary biliary cirrhosis: a staged model approach
    C W Chan
    The Royal Free Sheila Sherlock Liver Centre and Division of Surgery, Royal Free Hospital, Hampstead, London, UK
    Aliment Pharmacol Ther 31:573-82. 2010
    ..Aim To describe a prognostic model for the advent of complications in primary biliary cirrhosis as the first approach to a staged prognostic model...
  77. pmc The lymphatic vascular system in liver diseases: its role in ascites formation
    Chuhan Chung
    Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
    Clin Mol Hepatol 19:99-104. 2013
    ..vessels) and changes in the properties of lymphatic vessels are associated with pathogenesis of tumor metastases, ascites formation, liver fibrosis/cirrhosis and portal hypertension...
  78. ncbi Microparticles from ovarian carcinomas are shed into ascites and promote cell migration
    Joshua Z Press
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle, WA, USA
    Int J Gynecol Cancer 22:546-52. 2012
    ..We compared microparticles in ascites between women with ovarian carcinoma and women with benign ovarian pathology, and isolated tumor-derived (..
  79. ncbi The detection of bacterial DNA in blood of rats with CCl4-induced cirrhosis with ascites represents episodes of bacterial translocation
    Carlos Guarner
    Liver Section, Escuela de Patologia Digestiva, Hospital de la Sta Creu i St Pau, Barcelona, and Liver Unit, Hospital General Universitario, Alicante, Spain
    Hepatology 44:633-9. 2006
    Bacterial DNA (bactDNA) is present in blood and ascitic fluid (AF) in a third of patients with cirrhosis and ascites, but whether this phenomenon represents episodes of bacterial translocation (BT), strictly considered when culture of ..
  80. ncbi Intraperitoneal application of rituximab in refractory mantle cell lymphoma with massive ascites resulting in local and systemic response
    Martina Crysandt
    Medizinische Klinik IV, Universitaetsklinikum Aachen, RWTH Aachen, Aachen, Germany
    Eur J Haematol 79:546-9. 2007
    ..The patient's general status declined and she developed massive ascites as the dominant clinical problem...
  81. ncbi Malignant ascites symptom cluster in patients referred for paracentesis
    Amna Husain
    Temmy Latner Centre for Palliative Care, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
    Ann Surg Oncol 17:461-9. 2010
    Malignant ascites (MA) is a distressing problem usually managed by repeated paracenteses. Paracentesis represents a meaningful time point in identifying patients with a specific presentation.
  82. pmc Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients
    Denis Lane
    Departement De Microbiologie et Infectiologie, Faculte de Medecine, Universite de Sherbrooke, 3001, 12ième Avenue Nord, Sherbrooke, J1H 5N4, Canada
    BMC Cancer 11:210. 2011
    The acellular fraction of epithelial ovarian cancer (EOC) ascites promotes de novo resistance of tumor cells and thus supports the idea that tumor cells may survive in the surrounding protective microenvironment contributing to disease ..
  83. ncbi Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites
    Seung Up Kim
    Department of Internal Medicine, Yonsei University, College of Medicine, Seoul, South Korea
    J Gastroenterol Hepatol 23:1722-7. 2008
    Few studies have assessed the natural history of hepatitis B virus (HBV)-related cirrhotic ascites. We investigated the natural history of patients with HBV-related cirrhotic ascites hospitalized to control ascites and determined their ..
  84. ncbi Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study
    Peter Jepsen
    Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
    Hepatology 51:1675-82. 2010
    ..We examined prevalence, risk, chronology, and mortality associated with three complications of cirrhosis: ascites, variceal bleeding, and hepatic encephalopathy...
  85. ncbi Clinical characteristics and outcome of patients with cirrhosis and refractory ascites
    Richard Moreau
    Service d Hépatologie and INSERM U 481, 92118 Clichy, France
    Liver Int 24:457-64. 2004
    In patients with cirrhosis, refractory ascites is associated with a poor prognosis and is an indication for liver transplantation. However, factors that determine prognosis remain unclear.
  86. ncbi Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration
    Monica Guevara
    Liver Unit Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
    Liver Int 30:1137-42. 2010
    ..intrahepatic portosystemic shunts (TIPS) vs large-volume paracentesis in the management of refractory of ascites. Variables used in the analysis included age, sex, previous history of HE, treatment assignment (TIPS vs large ..
  87. ncbi Genetic parameters of ascites-related traits in broilers: effect of cold and normal temperature conditions
    A Pakdel
    Animal Breeding and Genetics Group, Wageningen Institute of Animal Sciences, Wageningen, The Netherlands
    Br Poult Sci 46:35-42. 2005
    1) Ascites syndrome is a growth-related disorder of broilers that occurs more often in fast-growing birds and at low temperatures...
  88. ncbi The use of albumin in all patients with decompensated cirrhosis is not justified
    Benjamin Avidan
    Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel
    Isr Med Assoc J 7:118-20. 2005
  89. ncbi A novel perspective for an orphan problem: old and new drugs for the medical management of malignant ascites
    S Barni
    Division of Medical Oncology, Azienda Ospedaliera Treviglio Caravaggio, Treviglio Caravaggio Hospital, Treviglio BG, Italy
    Crit Rev Oncol Hematol 79:144-53. 2011
    Malignant ascites is defined as a condition in which fluid containing cancer cells accumulates in the abdomen...
  90. ncbi Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites
    Jasmohan S Bajaj
    Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, McGuire VA Medical Center, Virginia Commonwealth University, Richmond, Virginia 23221, USA
    Am J Gastroenterol 104:1130-4. 2009
    Spontaneous bacterial peritonitis (SBP) is a frequent complication of cirrhosis. Bacterial contamination of ascites fluid leading to SBP is caused by bacterial translocation with subsequent bacteremia...
  91. ncbi Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity
    Florence Wong
    Department of Medicine, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada
    Gut 61:108-16. 2012
    Satavaptan, a vasopressin V2 receptor antagonist, has been shown to improve the control of ascites in cirrhosis in short-term phase II studies...
  92. ncbi LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites
    Mayumi Komachi
    Laboratory of Signal Transduction, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Japan
    Carcinogenesis 30:457-65. 2009
    Malignant ascites from pancreatic cancer patients has been reported to stimulate migration of pancreatic cancer cells through lysophosphatidic acid (LPA) and LPA(1) receptors...
  93. ncbi Alcohol consumption by cirrhotic subjects: patterns of use and effects on liver function
    Michael R Lucey
    Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53792 5124, USA
    Am J Gastroenterol 103:1698-706. 2008
    ....
  94. ncbi Malignant ascites: past, present, and future
    Rony A Adam
    Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA 30303, USA
    J Am Coll Surg 198:999-1011. 2004
  95. ncbi Renal replacement therapy in end-stage renal disease patients with chronic liver disease and ascites: role of peritoneal dialysis
    Kunal Chaudhary
    Division of Nephrology, University of Missouri Health Center, Columbia, MO 65203, USA
    Perit Dial Int 28:113-7. 2008
    ..ESRD patients with chronic liver disease and ascites are more difficult to manage on hemodialysis (HD) due to their hemodynamic status and risk of bleeding...
  96. ncbi Development of an experimental model of induced bacterial peritonitis in cirrhotic rats with or without ascites
    Elisabet Sánchez
    Liver Unit, Hospital de la Santa Creu i Sant Pau, Autonomous University, Barcelona, Spain
    Am J Gastroenterol 102:1230-6. 2007
    ..Spontaneous bacterial peritonitis (SBP) is a severe complication of cirrhotic patients associated with a high mortality...
  97. ncbi Differential gene expression of proinflammatory chemokines and cytokines in lungs of ascites-resistant and -susceptible broiler chickens following intravenous cellulose microparticle injection
    Krishna R Hamal
    Department of Poultry Science, University of Arkansas, Fayetteville, AR 72701, USA
    Vet Immunol Immunopathol 133:250-5. 2010
    ..of microparticles (MPs) is a tool to reveal susceptibility to pulmonary hypertension (PH) syndrome (PHS, ascites) in broilers. After injection MPs get lodged in pulmonary arterioles and cause localized inflammation...
  98. ncbi Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1
    Takayuki Yamada
    Laboratory of Signal Transduction, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi 371 8512, Japan
    J Biol Chem 279:6595-605. 2004
    Cytokines and growth factors in malignant ascites are thought to modulate a variety of cellular activities of cancer cells and normal host cells...
  99. ncbi Prognostic value of serum and ascites levels of estradiol, FSH, LH and prolactin in ovarian cancer
    Frank Chih Kang Chen
    Department of Gynecology and Obstetrics Charité University Medicine Berlin Campus Virchow Klinikum Augustenburger Platz 1, 13353 Berlin, Germany
    Anticancer Res 29:1575-8. 2009
    ..The aim of this study was to investigate the influence of sex hormone levels on tumor biology and patients' outcome in ovarian cancer...
  100. ncbi Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation
    Gianni Testino
    Unit of Hepato Gastroenterology Monoblocco 12, S Martino Hospital, Piazzale R Benzi 16132, Genova, Italy
    Hepatogastroenterology 50:1753-5. 2003
    ..Its role in the management of refractory ascites and hepatorenal syndrome still awaits further prospective studies...
  101. ncbi Ascites syndrome in broilers: physiological and nutritional perspectives
    A Baghbanzadeh
    Section of Physiology, Department of Basic Sciences, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
    Avian Pathol 37:117-26. 2008
    ..If this is not done, inefficient production and several metabolic diseases such as ascites become apparent...

Research Grants64

  1. Regulation of Ovarian Cancer Multidrug Resistance by MAP Kinases
    Scott T Eblen; Fiscal Year: 2013
    ..We generated phospho-specific antibodies and have shown SPF45 phosphorylation in human ascites and in cell lines in response to chemotherapeutic drugs, oxidative stress, phorbol esters and UV irradiation...
  2. Molecular mechanism of antiangiogenic properties of gold nanoparticle
    Priyabrata Mukherjee; Fiscal Year: 2013
    ..It is likely that it will bind to all the pro-angiogenic heparin-binding growth factors present in the ascites and inhibit their function...
  3. Synergistic actions by multiple Toll-like receptors in alcoholic liver disease
    Ekihiro Seki; Fiscal Year: 2013
    ..Not only LPS, but also bacterial DNA levels in blood and ascites are elevated in patients with alcoholic-induced liver cirrhosis...
  4. Role of the CNS in Inappropriate Vasopressin Release Associated with Cirrhosis
    JOSEPH D WALCH; Fiscal Year: 2013
    ..Problem: Hepatic cirrhosis is a chronic, progressive disease that is associated with ascites and hyponatremia...
  5. Tumor metastasis: Biobehavioral mechanisms
    Anil K Sood; Fiscal Year: 2009
    ..protective effects against anoikis and determine in vivo effects of stress on protection of tumor cells in ascites against apoptosis (in vivo reflection of anoikis avoidance by tumor cells)...
  6. Integrating plasma IGF-1 into novel classification of hepatocellular carcinoma
    Ahmed Kaseb; Fiscal Year: 2013
    ..measuring serum bilirubin level, in addition to two subjective clinical parameters, hepatic encephalopathy and ascites. The last two parameters are clinically difficult to grade, may be precipitated by other nonliver diseases, and ..
  7. Central Kappa Opioid Neural Regulation of Cardiovascular and Renal Function
    Helmut B Gottlieb; Fiscal Year: 2012
    In certain pathophysiological states (e.g., cirrhoses with ascites), changes in the integrity of arterial circulation can lead to profound changes in renal excretion of fluid and electrolytes via the activation of neuronal and humoral ..
  8. Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension
    Flemming Forsberg; Fiscal Year: 2013
    ..DESCRIPTION (provided by applicant): Common complications of portal hypertension include gastroesophageal varices, ascites, and portasystemic encephalopathy...
  9. Regulation of lipogenesis by lysophosphatidic acid in ovarian cancer
    Xianjun Fang; Fiscal Year: 2012
    ..In our preliminary studies, lysophosphatidic acid (LPA), a growth factor-like mediator present in ascites of ovarian cancer patients, stimulated de novo lipid synthesis in ovarian cancer cells through regulation of the ..
  10. Noninvasive and Accurate Measurement of Portal Hypertension
    Flemming Forsberg; Fiscal Year: 2010
    ..Common complications of portal hypertension include gastroesophageal varices, ascites, and portasystemic encephalopathy...
  11. Multifunctional Nanotherapeutics for Cancer Treatment and Imaging
    Tamara Minko; Fiscal Year: 2013
    ..human multidrug resistant ovarian cancer cell lines as well as cells isolated from primary tumor and malignant ascites from patients with advanced multidrug resistant ovarian carcinoma will be used to create ectopic subcutaneous and ..
  12. Quantitative Hemodynamics of the Liver with 4D Flow MRI
    Oliver Wieben; Fiscal Year: 2013
    ..collaterals (varices) that shunt blood from the liver, renal dysfunction (hepatorenal syndrome), accumulation of ascites, among other complications...
  13. Tissue procurement &processing for molecular analysis
    Christopher A Moskaluk; Fiscal Year: 2013
    ..of lymphocytes disaggregated from lymph nodes and frozen cell suspensions of viable cells obtained from ascites fluid. In addition to paraffin embedding, histologic sections of paraffin embedded or frozen tissue are offered...
  14. The Impact of the MELD Score at the Time of Listing for Liver Transplantation
    Alyson N Fox; Fiscal Year: 2010
    ..of liver disease or having had a complication of portal hypertension prior to listing (hyponatremia, refractory ascites, spontaneous bacterial peritonitis, variceal hemorrhage, or encephalopathy of sufficient severity to require ..
  15. Novel extra cellular RNA-based combinatorial RNA inhibition therapy
    Anil K Sood; Fiscal Year: 2013
    ..based on secretion measurements, by small RNA deep sequencing in "paired" samples from tumors, plasma and ascites from the same patient, and by functional studies for the lead exRNA candidates...
  16. Exploiting Biological Networks to Improve Clinical Treatment of Ovarian Cancer
    Andrew K Godwin; Fiscal Year: 2013
    ..validated dasatinib-sensitizing siRNAs by screening a set of EOC cell lines and primary cultures generated from ascites obtained from patient with ovarian cancer and cluster these sensitizing genes into coordinated groups based on ..
  17. Functional Imaging of the Metastatic Phenotype
    Zaver M Bhujwalla; Fiscal Year: 2013
    ..prostate cancer invasion and metastasis with a focus, in this application, on lymphatic metastasis and malignant ascites. During the previous funding period we have obtained novel insights into metastasis-permissive environments and ..
  18. Roles of inflammation-driven chemokines in the pathogenesis of ovarian cancer
    Deok Soo Son; Fiscal Year: 2013
    ..Growth-regulated oncogene (CXCL1) was significantly increased in ovarian cancer cells, and in the plasma and ascites of patients with ovarian cancer...
  19. Epidermal growth factor regulation of miR-125a promotes invasive ovarian cancer
    KAREN DENISE COWDEN DAHL; Fiscal Year: 2012
    ..of miR-125a to invasive potential by regulating invasive targets, and 3) analyze human tumors and malignant ascites for miR-125a expression to establish whether the expression of miR-125a is altered in ovarian cancer...
  20. Epidermal growth factor regulation of miR-125a promotes invasive ovarian cancer
    KAREN COWDEN DAHL; Fiscal Year: 2009
    ..of miR-125a to invasive potential by regulating invasive targets, and 3) analyze human tumors and malignant ascites for miR-125a expression to establish whether the expression of miR-125a is altered in ovarian cancer...
  21. Integrated Microdevice to Capture and Detect Circulating Tumor Cells
    RICHARD JAMES COTE; Fiscal Year: 2011
    ..a microchip device for processing blood, and eventually bone marrow and other fluids like pleural effusions or ascites. This microdevice, coupled with microfluidics, has the potential to revolutionize the approach to tumor cell ..
  22. Apoptosis Inducing to Enhance Tumor Targeting
    Ze Lu; Fiscal Year: 2012
    ..survival compared to untreated controls) in both early and late stage diseases (indicated by carcinomatosis or ascites formation) in mice bearing the rapidly growing human pancreatic Hs766T xenograft tumors and the slowly growing ..
  23. CIRRHOSIS AND ITS COMPLICATIONS
    Guadalupe Garcia Tsao; Fiscal Year: 2009
    ..recommendation of using large-volume paracentesis + albumin as standard of care in the treatment of refractory ascites. As a rational followup to this study, Dr...
  24. The Role of the Microenvironment in Early Ovarian Cancer Metastasis
    HILARY ANN KENNY; Fiscal Year: 2010
    ..of our studies is to identify early intraperitoneal treatment that inhibits OvCa cell (primary tumor or ascites-derived) adhesion (i.e. MMP-2 selective inhibitor) to the peritoneal cavity and metastasis...
  25. Re-activating Memory T Cells in the Microenvironment of Human Tumors
    Richard B Bankert; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Human memory T cells present in ovarian tumor ascites fluids fail to respond to stimulation via the T cell receptor (TCR)...
  26. ESOPHAGEAL VARICES BY B-ADRENERGIC BLOCKERS
    Roberto Groszmann; Fiscal Year: 2003
    ..but because it may prevent or delay the development of other complications of portal hypertension, such a ascites. This ongoing multi-center, prospective, randomized, placebo-controlled, double-blind trial was designed with the ..
  27. Modulation of RGS proteins and Ovarian Cancer Chemoresistance
    MANDI M contact MURPH; Fiscal Year: 2011
    ..In ovarian cancer, LPA is a growth factor found in patient ascites fluid that enhances tumor progression by promoting oncogenic growth and survival signaling...
  28. Receptor Cross-Talk in Early Metastatic Dissemination
    MARY SHARON STACK; Fiscal Year: 2013
    ..the peritoneal cavity followed by intra-peritoneal (IP) implantation, and is often associated with peritoneal ascites. The factors that regulate the terminal transition from free-floating MCA to life-threatening peritoneally ..
  29. Development of therapeutic monoclonal antibody to the bioactive lipid lysophospha
    Rosalia Matteo; Fiscal Year: 2009
    ..LPA is elevated in sera and ascites fluid of patients with early and late stage disease...
  30. Molecular Mechanisms of Cell Invasion
    CRISLYN D'SOUZA-SCHOREY; Fiscal Year: 2013
    ..recent accruing evidence demonstrating the bona fide presence of microvesicles in body fluids (blood, urine and ascites), and their potential to serve as indicators of disease, has extended interest and intensified research efforts ..
  31. DETERMINANTS OF SODIUM RETENTION IN CIRRHOSIS
    WILLIAM RECTOR; Fiscal Year: 1992
    The cause of ascites in patients with cirrhosis is not established...
  32. METHODOLOGIC RESEARCH IN SIMULATING COMPLEX DISEASE
    Mark Roberts; Fiscal Year: 1991
    ..of disease-related death, and produces substantial morbidity and decreases quality of life when patients develop ascites, encephalopathy or bleeding varices...
  33. Effect of Cirrhosis and Shunts on Drug Disposition
    Stephen Hall; Fiscal Year: 2006
    ..major complications of cirrhosis such as bleeding from gastroesophageal varices, hepatic encephalopathy, and ascites. Transjugular intrahepatic portosystemic shunts (TIPS) and other surgical shunts are performed to manage these ..
  34. Targeted Proapoptotic Anticancer Drug Delivery Systems
    Tamara Minko; Fiscal Year: 2010
    ..However, they were less efficient in cells isolated from primary human ovarian tumor and intraperitoneal ascites which possess intrinsic MDR or acquired such resistance during previous courses of chemotherapy...
  35. Peritumorally transformable nanoparticles for intraperitoneal chemotherapy of ova
    Yoon Yeo; Fiscal Year: 2010
    ..Simultaneously, in Aim 2, we will determine in-vivo MMP levels in normal tissues, ascites, and tumor tissues in an orthotopic xenograft model of human ovarian cancer...
  36. ALDOSTERONE, RENIN AND PROSTAGLANDINS IN MAN
    Richard Horton; Fiscal Year: 1980
    ..In preliminary studies we find that ascites patients have 10-fold increase in PGE, that prostaglandin inhibitors reduce renin (PRA) and aldosterone, reverse ..
  37. ECTO 5'-NUCLEOTIDASE AS A CELL SURFACE REPORTER
    KERMIT CARRAWAY; Fiscal Year: 1980
    ..Recent studies from our laboratory have shown that the coperativity in mammary ascites tumor cells is sensitive to drugs which perturb the cellular cytoskeleton and to intracellular Ca ions...
  38. TRIPTYCENE ANALOGS--NOVEL BIFUNCTIONAL ANTICANCER DRUGS
    Jean Pierre Perchellet; Fiscal Year: 2004
    ..TT2 derivatives can inhibit tumor development in vivo and prolong the survival of mice challenged with ascites (L1210) or solid tumors with metastatic potential (Lewis lung carcinoma and B16F10 melanoma)...
  39. Multifunctional roles of homeobox gene DLX4 in ovarian cancer
    Honami Naora; Fiscal Year: 2013
    ..expressed in normal ovary and benign cysts, whereas its expression in malignant EOC is strongly associated with ascites, high tumor grade and advanced disease stage...
  40. Liver Derived Microparticles In Cirhossis Pathogenesis
    RAFAL WITEK; Fiscal Year: 2009
    ..of cirrhosis, including cutaneous spider telangectases, cachexia, increased intestinal permeability, ascites and the hepatorenal syndrome, the portopulmonary syndrome, and hepatic encephalopathy...
  41. PATHOGENESIS AND THERAPY OF B19-INDUCED HYDROPS FETALIS
    Cathy Carlson; Fiscal Year: 2000
    ..e., presence of ascites, pleural or pericardial effusions) if present...
  42. REGULATION OF CSF 1 AND UROKINASE IN OVARIAN CANCER
    SETSUKO CHAMBERS; Fiscal Year: 1999
    ..Moreover studies of the role of uPA, its receptor, and its inhibitors in ascites of ovarian cancer patients suggests that uPA is an important protease in the biology of ovarian cancer...
  43. Gene Regulation for Drug Targeting in AML
    Manohar Ratnam; Fiscal Year: 2009
    ..The ATRA effect conferred a substantial therapeutic benefit, on FR-targeted liposomal doxorubicin, in a mouse ascites tumor model of AML...
  44. LYMPHOCYTE/TUMOR INTERACTIONS IN SCID/HU CHIMERIC MICE
    Albert Donnenberg; Fiscal Year: 1993
    ..The development of this model depends upon three elements: 1) our ability to separate human malignant ovarian ascites into highly enriched populations of tumor cells, lymphocytes, and monocytes by counterflow centrifugal ..
  45. CELL DEATH, CHALONES, AND CYTOTOXIC METABOLITES
    Martin Murphy; Fiscal Year: 1993
    ..Preliminary data obtained with the cyst fluid from blastocyst-like embryoid bodies of the ascites form of a teratocarcinoma suggest that cytotoxic polyamine metabolites, generated by the activities of amine ..
  46. MECHANISM OF NANAASE-ENHANCED TUMOR IMMUNOGENICITY
    JACK PINCUS; Fiscal Year: 1980
    ..We have developed a chemoimmunotherapy model for treating L1210 ascites tumors in DBA/2J mice by combining 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosurea (MeCCNU) with NANAase-..
  47. BIOLOGY OF SOLID & ASCITES TUMOR GROWTH
    HAROLD DVORAK; Fiscal Year: 1992
    ..Accumulation and turnover of fibrinogen/fibrin will be compared in solid tumors, in defined skin wounds, and in ascites tumors where malignant cells grow in suspension without constraints imposed by connective tissue stroma...
  48. STUDY FOR THE TREATMENT OF REFRACTORY ASCITES
    Arun Sanyal; Fiscal Year: 2000
    DESCRIPTION Refractory ascites is a serious complication of cirrhotic portal hypertension and is associated with considerable morbidity, increasing health costs, decreasing quality of life and eventually death or increased risk of death ..
  49. Novel, cost-effective production of immunoaffinity Abs
    Scott Franklin; Fiscal Year: 2006
    ..including culture of hybridomas, re-introduction of hybridomas into mice and subsequent generation of ascites and transfection of mammalian cell lines with specific heavy and light chain antibody genes...
  50. ACTIN-CONTAINING TRANSMEMBRANE COMPLEX OF TUMOR CELLS
    KERMIT CARRAWAY; Fiscal Year: 1990
    ..As a model system for studying these interactions, we use two ascites sublines of the 13762 rat mammary adenocarcinoma...
  51. RETROVIRAL GAG PROTEIN BINDING TO TYROSINE KINASES
    CORALIE CARRAWAY; Fiscal Year: 2001
    ..p58gag, the product of an expressed endogenous retroviral sequence, from a highly malignant 13762 rat mammary ascites tumor...
  52. Apoptosis Inducing to Enhance Tumor Targeting
    Ze Lu; Fiscal Year: 2004
    ..These patients usually present with multiple solid tumors and malignant ascites in the peritoneal cavity that are not adequately managed by systemic intravenous (iv) therapy...
  53. Spontaneous regression of late stage tumors
    Zheng Cui; Fiscal Year: 2002
    ..through unexpected observations, a unique mouse mutation conferring the spontaneous regression of late-stage ascites induced by the transplantation of very aggressive mouse sarcoma 180 cells...
  54. MINORITY PREDOCTORAL FELLOWSHIP PROGRAM
    JERRY SAUNDERS; Fiscal Year: 2006
    ..is a prevalent cause of death in women, and progressive stages of this disease are hallmarked by accumulation of ascites fluid in the abdominal cavity...
  55. Tumor environmental CD4+CD25+ T cells
    Weiping Zou; Fiscal Year: 2006
    ..we thus propose to examine the function and generation of human CD4 + Tr tumor infiltrating lymphocytes from the ascites of ovarian cancer patients in a novel in vivo NOD/SCID model. Our specific aims are: Aim 1...
  56. BIOCHEMICAL ASPECTS OF GENE REGULATION
    MICHAEL DAHMUS; Fiscal Year: 1980
    ..The activity of highly purified Novikoff ascites tumor RNA polymerase I and II is stimulated by the presence of a purified nuclear protein kinase...
  57. INTRAPERITONEAL AD5-P53 GENE THERAPY FOR OVARIAN CANCER
    Robert Coleman; Fiscal Year: 1999
    ..Since the spread of advanced ovarian cancer typically remains in the peritoneal compartment and tumor cells in ascites are easily accessible for biologic studies, intraperitoneal administration of Ad5-p53 is an ideal model to use in ..
  58. TARGETING AND THERAPY OF TUMORS WITH MONOCLONAL ANTIBODY
    TSANN CHU; Fiscal Year: 1990
    ..expresses antigen recognized by monoclonal antibody F36/22 and resembles the human disease by producing ascites and intra-abdominal carcinomatosis...
  59. ENHANCEMENT OF HSV-TK GENE THERAPY IN CANCER
    Douglas Yee; Fiscal Year: 2000
    ..adenoviral transfer of the herpes simplex virus thymidine kinase gene (HSV-tk) to malignant cells growing as ascites tumors in nude mice, thus enabling these cells to metabolize the nucleoside analog ganciclovir (GCV) to a lethal ..
  60. Y2, A NOVEL OVARIAN CANCER TUMOR SUPPRESSOR GENE
    Robert Bast; Fiscal Year: 2000
    ..expression was lost in 11 of 12 ovarian cancer cell lines, 9 of 9 primary ovarian cancer cell specimens from ascites and 5 of 7 paraffin blocks of solid ovarian Cas...
  61. OVARIAN CANCER ANTI ANGIOGENIC FACTOR
    Vikas Sukhatme; Fiscal Year: 2001
    ..This proposal focuses on the isolation and initial characterization of factors derived from human ovarian cancer ascites and conditioned medium (CM) from an ovarian cancer cell line...
  62. PROTECTION AGAINST IL12 TOXICITY BY CNI1493
    CLARISSA NAFTZGER; Fiscal Year: 1999
    ..addition to lethal doses of IL-12 survived longer and exhibited fewer severe side effects, which included reduced ascites, reduced lymphoid cell infiltration of normal tissues, and reduced lymphoid organ destruction...
  63. Gene Expression of Viable Ovarian Cancer Cells
    Wen Tien Chen; Fiscal Year: 2003
    ..Current technology to enrich for metastatic ovarian cancer cells from ascites at the time of surgery involves using a combination of centrifugation and positive- and negative-selecting immuno-..
  64. Antibody Therapy Targeting a Novel Neuroblastoma Antigen
    Susan Wright; Fiscal Year: 2005
    ..A panel of 4 - 6 mAbs will be produced and purified from mouse ascites fluid...